Market potential Explore partnerships around proprietary microRNA based diagnostics such as RosettaGX Reveal and RosettaGX Cancer Origin, targeting oncology clinics, pathology labs, and endocrinology practices that could benefit from expanded molecular testing menus.

Expansion signals Leverage the company’s CAP-accredited CLIA-certified labs in Philadelphia and Lake Forest to position Rosetta Genomics as a scalable supplier for larger hospital networks seeking validated molecular diagnostics and standardized workflows.

Strategic partnerships Identify collaboration opportunities with oncology, urology, pathology, and endocrinology providers to co-develop testing protocols, integrate FISH, IHC, and PCR capabilities, and bundle microRNA assays with existing diagnostic services.

Competitive positioning Highlight Rosetta Genomics’ earlier market presence and ongoing IP-driven microRNA discovery to differentiate from competitors by offering unique biomarker panels and actionable clinical recommendations through OncoGxOne-related capabilities and other assays.

Growth and finances Given revenue in the lower tens of millions and a history of acquisition activity, approach potential buyers or strategic investors with a value proposition around scalable lab operations, integrated diagnostic workflows, and opportunities for portfolio expansion in cancer origin testing.